# Mahana Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mahana-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.mahanatx.com
- Total disclosed funding: $73M
- Latest round: Series B (Aug 11, 2021)
- Investors on record: 6

## About

Mahana Therapeutics, Inc. is a US-based company specializing in digital therapeutics, aimed at improving patient outcomes through innovative software solutions tailored for healthcare applications.Founded in 2018 and headquartered in San Francisco, US, Mahana Therapeutics focuses on delivering digital therapeutic solutions. The company has been actively involved in three funding deals, most recently raising USD 61.00 mn in a Series B round. This funding was led by investors including Gurnet Point Capital and JAZZ Venture Partners. The firm was co-founded by Simon Levy, who has a history of leading technology initiatives in healthcare.Mahana Therapeutics primarily offers innovative software solutions that enhance operational efficiency and patient care in the healthcare sector. Their proprietary platforms streamline workflows, provide data analytics, and improve patient engagement. These products cater to various healthcare use cases, automating tasks for healthcare providers while delivering actionable insights to enhance patient management. The company serves a diverse clientele, including hospitals and healthcare practitioners, with a growing presence in North America and Europe.Mahana Therapeutics employs a revenue model based on subscription services and direct product sales. Clients typically sign annual subscription agreements that include software updates and customer support. Additionally, the company offers multi-user licenses for its core platform, allowing businesses to scale their usage effectively. Strategic partnerships with wholesalers further enable broader distribution, contributing to recurring revenue streams and customer retention in the healthcare software market.Looking ahead, Mahana Therapeutics plans to leverage its recent acquisition by Nerva, which will enhance access to their digital therapeutics database and technology. The acquisition, completed in May 2025, aligns with their strategy to improve service delivery for consumers. The company aims to expand its product offerings and enter new markets, particularly targeting Europe and Asia by the end of 2026. Recent funding will support these initiatives, facilitating the development of upcoming products designed to enhance patient outcomes and operational efficiencies.

## Funding rounds

- Series B, Aug 11, 2021, $61M — Lux Capital, KKCG, Gurnet Point Capital, JAZZ Venture Partners, Main Street Advisors
- Seed, Jan 10, 2020, $12M — Lux Capital, JAZZ Venture Partners, Luminous Ventures

## Investors

- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Seed, Series B
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Seed, Series B
- Luminous Ventures — Seed
- KKCG (https://capitalatlas.ai/funds/kkcg) — Series B
- Gurnet Point Capital (https://capitalatlas.ai/funds/gurnet-point-capital) — Series B
- Main Street Advisors (https://capitalatlas.ai/funds/main-street-advisors) — Series B